Proteins Binding to Cisplatin-Damaged DNA in Human Cell Lines

References

• Semin Oncol 1991; 18(1)1–87, (Suppl 3)
   Google Scholar
• Dewit L. Combined treatment of radiation and cis-diammine-dichloroplatinum (II): A review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403–426
   PubMed Web of Science ®Google Scholar
• Raghavan D, Pearson B, Watt WH, Mameghan H, Langdon P, Eisinger D, Wines R. Cytotoxic chemotherapy for advanced bladder cancer: Cisplatin containing regimens. Semin Oncol 1991; 18: 56–63
   PubMed Web of Science ®Google Scholar
• Alberts DS, Garcia D, Mason-Liddil N. Cisplatin in advanced cancer of the cervix: An update. Semin Oncol 1991; 18: 11–24
   PubMed Web of Science ®Google Scholar
• Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1991; 18: 222–232
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, Vance RB, Lambuth BW. Chemotherapy in ovarian carcinoma: Present role and future prospects. Semin Oncol 1989; 16: 58–65
   PubMed Web of Science ®Google Scholar
• Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1991; 8: 1777–1781
   Web of Science ®Google Scholar
• Aisner J, Abrams J. Cisplatin for small-cell lung cancer. Semin Oncol 1989; 16: 2–9
   PubMed Web of Science ®Google Scholar
• Caradonna JP, Lippard SJ. Binding of the anti-tumor drug cis-diamminedichloroplatinum (II) (cisplatin) to DNA. Adv Chem Ser 1983; 209: 14–16
   Google Scholar
• Pinto AL, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum (II) (cisplatin) to DNA. Biochim Biophys Acta 1985; 780: 167–180
   PubMed Web of Science ®Google Scholar
• Fojo AT. Multidrug resistance. Adv Intern Med 1991; 36: 195–218
   PubMedGoogle Scholar
• Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J 1990; 272: 281–295
   PubMed Web of Science ®Google Scholar
• Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum (II). Biochemistry 1988; 27: 4730–4734
   PubMed Web of Science ®Google Scholar
• Masuda H, Ozols RF, Lai GM. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988; 48: 5713–5716
   PubMed Web of Science ®Google Scholar
• Kelley S, Basu A, Teicher BA. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813–1815
   PubMed Web of Science ®Google Scholar
• Phillips PC. Antineoplastic drug resistance in brain tumors. Neurol Clin 1991; 9: 383–404
   PubMed Web of Science ®Google Scholar
• Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC., Anderson ME. High resistance to cisplatin in human ovarian cancer is associated with marked increase in glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070–3074
   PubMed Web of Science ®Google Scholar
• Russo A, Carmichael J, De Friedman N., Graff W, Tochner Z, Glatstein E, Mitchell JB. The roles of intracellular glutathionine in antineoplastic chemotherapy. Int J Radiat Oncol Biol Phys 1986; 12: 1347–1354
   PubMed Web of Science ®Google Scholar
• Saburi Y, Makagawa M, Ono M, Masahura S, Muramatsu M, Kohno K, Kuwano M. Increased expression of glutathionine Stransferase gene in cis-diamminedichloroplatinum (II) resistant varients of Chinese hamster ovary cell line. Cancer Res 1989; 49: 7020–7025
   PubMed Web of Science ®Google Scholar
• Billings PC, Davis RJ, Engelsberg BN, Skov KA, Hughes EN. Characterization of high mobility group protein binding to cisplatin-damaged DNA. Biochem Biophys Res Commun 1992; 188: 1286–1294
   PubMed Web of Science ®Google Scholar
• Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 1992; 89: 2307–2311
   PubMed Web of Science ®Google Scholar
• Chao C CK, Huang SL, Lee LY, Lin-Chao S. Identification of inducible damage-recognition proteins that are overexpressed in HeLa cells resistant to cis-diamminedichloroplatinum (II). Biochem J 1991; 277: 875–878
   PubMed Web of Science ®Google Scholar
• Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 1990; 87: 3324–3327
   PubMed Web of Science ®Google Scholar
• Clugston CK, McLaughlin K, Kenny MK, Brown R. Binding of human single stranded DNA binding protein to DNA damaged by the anticancer drug cis-diamminedichloroplatinum (II). Cancer Res 1992; 52: 6375–6379
   PubMed Web of Science ®Google Scholar
• Donahue BA, Augot M, Bellon SF, Treiber DK, Toney JH, Lippard SJ, Essigmann JM. Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 1990; 29: 5872–5880
   PubMed Web of Science ®Google Scholar
• Hughes EN, Engelsberg BN, Billings PC. Purification of nuclear proteins that bind to cisplatin-damaged DNA: Identity with high mobility group proteins 1 and 2. J Biol Chem 1992; 267: 13520–13527
   PubMed Web of Science ®Google Scholar
• Pil PM, Lippard SJ. Specific binding of chromosomal protein HMGI to DNA damaged by the anticancer drug cisplatin. Science 1992; 256: 234–237
   PubMed Web of Science ®Google Scholar
• Toney JH, Donahue BA, Kellett P, Bruhn SL, Essigmann JM, Lippard SJ. Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum (II). Proc Natl Acad Sci USA 1989; 86: 8328–8332
   PubMed Web of Science ®Google Scholar
• Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475–1489
   PubMed Web of Science ®Google Scholar
• Redinbaugh MG., Turley RB. Adaptation of the bicinchoninic acid protein assay for use with microtiter plates and sucrose gradient fractions. Anal Biochem 1986; 153: 267–271
   PubMed Web of Science ®Google Scholar
• Bustin M, Lehn D, Landsman A.D. Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990; 1049: 231–243
   PubMed Web of Science ®Google Scholar
• Javaherian K, Sadeghi M, Liu LF. Nonhistone proteins HMGI and HMG2 unwind DNA double helix. Nucleic Acids Res 1979; 6: 3569–3580
   PubMed Web of Science ®Google Scholar
• Singh J, Dixon GH. High mobility group proteins 1 and 2 function as general class II transcription factors. Biochemistry 1990; 29: 6295–6302
   PubMed Web of Science ®Google Scholar
• Sheflin LG, Fucile NW, Spaulding SW. The specific interactions of HMG1 and HMG2 with negatively supercoiled DNA are modulated by their acidic C-terminal domains and involve cysteine residues in their HMG1/2 boxes. Biochemistry 1993; 32: 3238–3248
   PubMed Web of Science ®Google Scholar
• Bruhn SL, Pil PM, Essigmann JM, Housman DE, Lippard SJ. Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. Proc Natl Acad Sci USA 1992; 89: 2307–2311
   PubMed Web of Science ®Google Scholar
• Bootsma D, Hoeijmakers J HJ. The genetic basis of xeroderma pigmentosum. Ann Genet 1991; 34: 143–150
   PubMedGoogle Scholar
• Szymkowski DE, Yerema K, Essigmann JM, Lippard SJ, Wood RD. An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts. Proc Natl Acad Sci USA 1992; 89: 10772–10776
   PubMedGoogle Scholar
• Strathdee CA, Buchwald M. Molecular and cellular biology of Fanconi anemia. Am J Pedriatr Hematol Oncol 1992; 14: 177–185
   PubMedGoogle Scholar